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Abstract
Genome-wide association studies (GWAS) have identified around 60 common variants associated with multiple sclerosis
(MS), but these loci only explain a fraction of the heritability of MS. Some missing heritability may be caused by rare variants
that have been suggested to play an important role in the aetiology of complex diseases such as MS. However current
genetic and statistical methods for detecting rare variants are expensive and time consuming. ‘Population-based linkage
analysis’ (PBLA) or so called identity-by-descent (IBD) mapping is a novel way to detect rare variants in extant GWAS
datasets. We employed BEAGLE fastIBD to search for rare MS variants utilising IBD mapping in a large GWAS dataset of 3,543
cases and 5,898 controls. We identified a genome-wide significant linkage signal on chromosome 19 (LOD=4.65;
p = 1.961026). Network analysis of cases and controls sharing haplotypes on chromosome 19 further strengthened the
association as there are more large networks of cases sharing haplotypes than controls. This linkage region includes a
cluster of zinc finger genes of unknown function. Analysis of genome wide transcriptome data suggests that genes in this
zinc finger cluster may be involved in very early developmental regulation of the CNS. Our study also indicates that BEAGLE
fastIBD allowed identification of rare variants in large unrelated population with moderate computational intensity. Even
with the development of whole-genome sequencing, IBD mapping still may be a promising way to narrow down the region
of interest for sequencing priority.
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Introduction
Multiple sclerosis (MS) is a complex neurological disease of the
central nervous system (CNS) triggered by environmental and
genetic factors. There is considerable evidence for a significant
genetic component to MS susceptibility, such as a higher
concordance rate in monozygotic twins (24%–30%) than dizygotic
twins (3%–5%) [1,2]. As for other immune diseases, genome-wide
association studies (GWAS) have been highly successful for MS:
uncovering around 60 common genetic variants associated with
disease [3–13]. The majority of these variants lie near genes with
known functions in the immune system and these variants have
also been associated with other autoimmune diseases, often in the
opposite direction [14]. Virtually all of the variants confer modest
increases in disease risk, the outstanding exception being the
strong association with the HLA-DRB1*15:01 allele in the major
histocompatibility complex (MHC), which was first detected in the
1970’s [15,16].
Despite this success, the variants identified by GWAS to date
only explain 18–24% of the heritability of MS [13,17]. While
much of the missing heritability is probably explained by common
variants of even smaller effect sizes, some heritability may be
explained by rare variants of larger effect size. Standard analysis of
GWAS data is not designed to detect associations with rare
variants that many believe may play an important role in the
aetiology of complex traits [18–20]. Interestingly, GWAS have
had less success for putative neurodegenerative diseases, such as
Parkinson’s disease, than for MS. For these diseases, family-based
approaches detecting rare variants have been more successful
[21,22]. This raises the possibility that rare variants under negative
selection pressure are relatively more important in the genetic
architecture of neurodegenerative processes, whereas common
variants under balancing selection are more important in the
genetic architecture of immunological processes. Discovery of rare
MS susceptibility variants may alter perspectives on the relative
importance of immunological & neurodegenerative processes in
MS onset.
Standard analyses of GWAS data are not designed to detect
associations with low frequency variants (MAF#5%), and other
strategies are required. One approach is to re-sequence loci
containing common susceptibility variants identified from GWAS
studies. This strategy was used to detect rare variants in IFIH1
conferring protection to type I diabetes [18]. However this strategy
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precludes the identification of new loci. Eventually it will be
possible to overcome this limitation by whole genome sequencing,
but it remains prohibitively expensive to perform adequately-
powered studies. An alternative is to re-analyse GWAS data using
identity-by-descent (IBD) mapping [23], also referred to as
‘population-based linkage analysis’ (PBLA) [24]. PBLA describes
linkage analysis applied at the population level to detect mega
base-scale regions where cases have inherited long haplotypes from
distant ancestors, 10–100 generations ago. IBD mapping is
performed on the unrelated individuals to determine whether
these mega-base scale regions are identical and inherited from a
common ancestor. If the common ancestor lived more than ten
generations ago the individuals will share very short tracts of
genetic material, and a shared haplotype that is very rare is also
very likely to be IBD. HapMap Phase 3 identified that lower
frequency variants should, on average, be younger than more
common variants; and thus display a greater extent of haplotype
sharing [25]. Therefore, if case pairs can be detected with long
shared haplotypes (generally one to five megabases) inherited from
distant common ancestors, then rare variants influencing disease
risk can be localised. Even when whole genome sequencing
becomes cheap enough to pursue with substantial sample sizes,
IBD mapping may still help reduce the massive multiple testing
problem by prioritizing regions. This is similar to the technique of
prioritising association signals in regions of linkage [26].
Several methods of IBD mapping have been published: these
include PLINK [24], GERMLINE [27], BEAGLE IBD [28] and
BEAGLE fastIBD [29]. The models employed by PLINK and
GERMLINE assume SNPs are in linkage equilibrium, and so
‘pruning’ of SNPs [24] is required to avoid false positives due to
under-estimates of population haplotype frequencies. However
pruning of SNPs in incomplete linkage disequilibrium (LD)
discards potentially useful information and reduces power.
BEAGLE IBD and fastIBD implement a variable length Hidden
Markov Model [30] to account for LD and model haplotype
frequencies more accurately. BEAGLE fastIBD runs considerably
faster than BEAGLE IBD (of the order of 1000 times faster with
large GWAS datasets). This is mainly because 1) it does not
formally model IBD status (‘IBD’/’not IBD’) between pairs of
individuals using a Hidden Markov Model as in BEAGLE IBD; 2)
it stores haplotype frequencies in a data dictionary (as in
GERMLINE) which means computational time scales with sample
size n like n log n instead of n2.
To detect MS rare variants, we here use BEAGLE fastIBD to
perform an IBD analysis on several large MS GWAS datasets
comprised 3543 cases and 5898 controls. We identified a region of
high significance on chromosome 19q13.43, with a genome-wide
significant localisation signal (p = 1.961026; LOD=4.65) using
thresholds based on IBD segment length greater than 3 cM and
the probability p-value less than 1029 (3cM_1e-9). This locus was
deemed genome-wide significant according to the recently
established genome-wide significance thresholds set for IBD
mapping [31]. Analysis of expression data and investigation of
genes in this area support the hypothesis for regulation of gene
expression in this region to impact upon development or health of
CNS tissue. Our analyses also illustrate some of the practical issues
to deal with in IBD analyses, and demonstrate that IBD mapping
can form a potentially powerful method for detecting rare variants
in unrelated individuals at the population level.
Methods
Study subjects
All the MS cases and controls were recruited and genotyped
from MS GWAS totaling 3,543 cases and 5,898 controls. Of these,
1,618 cases and 3,413 controls were from an Australian and New
Zealand MS GWAS conducted by the Australian and New
Zealand Multiple Sclerosis Genetics Consortium (ANZgene) [3],
and those DNA samples were genotyped on the Illumina Infinium
Hap370CNV array [3]. An additional 861 Australian and New
Zealand MS cases were genotyped with the Illumina Human660-
Quad chip as part of a GWAS performed by the International MS
Genetics Consortium (IMSGC) and the Wellcome Trust Case
Control Consortium-2 (WTCCC2) [13]. Controls included 1,531
unrelated Australian samples from a GWAS genotyped by
Queensland Institute of Medical Research (QIMR) with the
Illumina Human610-Quad chip [32], and 1064 MS cases and 954
controls genotyped with the SentrixH HumanHap550 BeadChip
from a GWAS conducted in the US (GeneMSA) [6] [accessed via
dbGAP].
Table 1. Sample numbers from GWAS (after cleaning).
GWAS dataset
Country of
origin
No.
Case
No.
Control Total No. SNPs
Cases Controls
ANZgene [3] AUS, NZ US, UK 1,608 3,404 5,012 300,900
WTCCC2 [13] AUS - 766 - 766 586,393
QIMR [32] - AUS - 1,516 1,516 529,292
GeneMSA [6] US US 878 805 1,683 550,677
Total 3,252 5,725 8,977 274,735*
*The number of SNPs that passed QC in all 4 GWAS datasets.
AUS = Australia, NZ =New Zealand.
doi:10.1371/journal.pone.0056379.t001
Figure 1. Plots of raw data of IBD with one point for each SNP.
The green region is obvious outstanding from the black line, which
indicates the proportion of case pairs in this region higher than that of
control pairs. The black line represents where the proportion of case
pairs equal to control pairs.
doi:10.1371/journal.pone.0056379.g001
IBD Mapping for Rare Variants in MS
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Quality control of data
Conservative quality control measures were imposed both on
the individual datasets before merging, and in the combined
dataset after merging: SNPs with call rates less than 0.95 or in
Hardy-Weinberg disequilibrium (p,1027) were discarded, as were
samples with call rates less than 0.98. Duplicates and close relatives
were also removed. This data cleaning was performed using
PLINK.
A principal components analysis (PCA) was conducted by
EIGENSTRAT [33] to exclude ancestry outliers and examine
population structure within the remaining samples. First, SNPs in
strong LD were pruned (using the PLINK – indep command with
options 50 5 1.5), and then we excluded previously identified
regions of high LD [34]. Outliers in the PCA were excluded using
standard settings in Eigenstrat (more than six standard deviations
from the mean along the first 10 principal components). All
chromosomal locations refer to Human genome version hg18.
Running BEAGLE fastIBD and results processing
The fastIBD analyses were conducted using BEAGLE (http://
faculty.washington.edu/browning/beagle/). In brief, genotypes
for the merged, cleaned dataset were converted to BEAGLE
format by using the linkage2Beagle.jar utility program. We then
used the BEAGLE method for phasing the data and identifying
IBD segments simultaneously, using the ‘fastibdthreshold’ option.
This procedure was run 10 times for each chromosome starting
with different seeds of the random number generator.
The output of these calculations was a series of ‘‘putative’’ IBD
segments shared between pairs of individuals. Each segment comes
with the following information attached: ids for the pair of
individuals, first and last SNPs in the IBD segment, length of the
segment in centimorgans, and probability of the two individuals
both carrying the segment if it was not IBD. We filtered these
segments using various maximum probabilities and minimum
segment lengths, as recommended in the BEAGLE manual.
Results from the 10 runs were combined by taking the union of
IBD segments detected in each run. From the final list of segments,
we wrote a Perl script to count numbers of case-case pairs (yi),
case-control pairs (ui) and control-control pairs (vi) estimated to
share haplotypes IBD at each SNP.
Analysis of IBD
We focused on the detection of loci where groups of cases have
inherited rare susceptibility alleles IBD. To do this, we modelled
IBD sharing yi in case-case pairs (‘‘case pairs’’) as a function of IBD
sharing in xi = ui + vi in case-control pairs and control-control
pairs combined (‘‘control pairs’’).
We tried various methods to model the yi as a function of the xi:
linear regression, negative binomial regression and Poisson
regression. Models were fitted using R [35] and goodness of fit
was assessed by examining diagnostic plots (SR_commands S1).
At SNPs i with more IBD sharing in cases than expected,
residuals zi from the fitted models should be large and positive. To
present residuals on a scale more familiar to geneticists, we
converted them to LOD scores using the formula LODi = zi2/
(2*loge(10).
At the SNPs with the highest LOD scores, we calculated the
proportions of case pairs sharing IBD in various populations, and
plotted networks of case and control pairs sharing IBD with each
other using the R network package (http://cran.rproject.org/
web/packages/network/index.html).
Results
Study samples from GWAS after cleaning
11 individuals were excluded due to call rates less than 0.98 and
an additional 202 individuals were excluded because they were
close relatives or duplicates. PCA was conducted on a subset of
77,856 SNPs not in LD, which were common to all sample sets.
Through successive iterations 251 outliers (37 AUS cases; 9 AUS
controls; 6 UK controls; 97 US cases; 102 US controls) were
excluded. All datasets overlapped well after the removal of outliers
(Figure S1). In summary, following cleaning there were 3,243
cases and 5,725 controls with 274,735 autosomal SNPs in the final
analysis (Table 1).
Results of IBD analysis
We detected IBD with the threshold of IBD segment greater
than 3 cM and the haplotype probability p-value less than 1029
(3cM_1e-9). A strong linkage signal was observed in the HLA
region (LOD=3.58), while the strongest signal in non-HLA region
was on chromosome 19 (LOD=4.65), which reached genome-
wide significance according to the recent established genome-wide
significance threshold set for IBD mapping [31].
Figure 1 is a scatterplot of case-pair sharing yi versus control-
pair sharing xi as each of the 274,735 SNPs i. Using different
colours to represent SNPs on different chromosomes, an outlier
group of SNPs with relatively high case pair sharing on one
chromosome stands out in green.
Fitting, testing Poisson model and converting to LOD
scores
From examination of diagnostic plots (Figure S2, S3, S4), we
found that the Poisson model provided the best fit for these data.
Figure 2 shows a plot of residuals from the Poisson model
converted to LOD scores. The highest linkage signal, correspond-
ing to the green outlier region in Figure 1, was observed on
chromosome 19 with LOD=4.65 and p=1.961026. As expected,
a strong signal also was observed in the HLA region (LOD=3.58;
Fig. 1).
Figure 2. Plot of linkage scores along the whole genome with
the IBD threshold of 3cM_1e-9 (shared haplotype segment
.3 cM and haplotype probability p,1029). Chromosome 19 has
the strongest linkage signal (LOD= 4.65).
doi:10.1371/journal.pone.0056379.g002
IBD Mapping for Rare Variants in MS
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Analysis of Linkage region on chromosome 19
The linkage region on chromosome 19 with LOD scores
between 3.65 and 4.65 is around 900kb in length (Hg18 chr19:
62,529,738–63,437,743 bp) and corresponds to a cluster of zinc
finger genes at 19q13.4, many of which have arisen by gene
duplication. None of the genes in this region have been previously
identified in published GWAS or associated with MS or
autoimmune diseases.
The genes in this region were examined to identify candidate
genes with putative roles, which could, impact on susceptibility to
MS. Published microarray expression data [36], profiling gene
expression in the human hippocampus over a broad developmen-
tal range, were downloaded from Gene Expression Omnibus [37],
series number GSE25219. Gene summary data was analysed in
Partek Genomics Suite version 6.6 (Partek Inc., St. Louis, MO,
USA) to generate expression profiles across all developmental
periods for genes in the linkage region. Many of these genes
exhibit similar expression profiles with high expression in early
time points and low expression after birth. To categorize this
observed trend, samples from a number of early foetal time
periods (3, 4 and 5) (described in [36]) were grouped together and
compared with expression of grouped samples from periods 9, 10,
11, and 12. Differential expression of exon level probe sets
between these two groups was then analysed. The data points
corresponding to individual probe sets, and representing expres-
sion changes between these two developmental stages, were then
aligned against the linkage region in a UCSC genome browser
view. Differentially expressed probe sets were filtered using a false
discovery rate adjusted p value cut off (1.5361023) equivalent to a
p value threshold of 0.01 and a fold change minimum 1.5. Those
probe sets that passed this threshold were plotted on the UCSC
browser screen view [38]. Genomic locations for Affymetrix exon
level probe sets within the linkage region were downloaded from
the UCSC table browser [39] and used to construct a bedGraph
file of expression changes. The green bars indicate a higher
expression in foetal time points compared to later time points.
Some fold changes for genes in this region are very high (4–6 fold
higher in foetal than post birth).
Although little is known about the majority of genes in this
region, ZNF274 is a DNA binding protein involved in regulation of
H3K9me3 methylation at the 39 end of some ZNF genes by
recruitment of the histone methyltransferase SETDB1, and the
corepressor TRIM28 (KAP1) [40]. To examine the pattern of
H3K9me3 methylation in this region, genomic data on H3K9me3
methylation and KAP1, SETDB1 and ZNF274 binding in K562
cells [40] was used to make custom bedGraph files for visualization
Figure 3. Screen shot from the UCSC genome browser illustrating expression regulation within the identified linkage region on
Chromosome 19 (hg18) (http://genome.ucsc.edu). Human Refseq gene models are shown at the bottom of the figure. Custom bedGraph tracks
illustrating expression regulation, as described in the manuscript, are shown. From top to bottom: (A) exon level expression fold change in
hippocampus (FDR adjusted p value,0.01 and fold change.1.5) between early fetal (periods 3,4 and 5) and postnatal (periods 9,10,11 and 12) from
Kang et al 2011, green bars indicate increased expression in fetal compared with postnatal and red bars indicate decreased expression in fetal
compared with postnatal. ChIP-chip binding patterns of (B) H3K9me3 (C) TRIM28/KAP1 (D) SETDB1 and (E) ChIP-seq binding pattern of ZNF274 in
K562 cells. For the ChIP-chip data log2 (ratio) values reflecting the ChIP enrichments are plotted on the Y axis. For the ChIP-seq data the number of
tags reflecting the ChIP enrichments are plotted on the Y axis. ChIP-chip and ChIP-seq data are from Frietze et al 2010 supplementary data.
Chromosomal coordinates and relative position on the chromosome is illustrated in the idogram at the top of the figure. The position of SNP
rs159870 is shown by a vertical black line.
doi:10.1371/journal.pone.0056379.g003
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alongside the expression change with development (Fig. 3). From
this data we observed that the vast majority of genes in this region
with high foetal expression levels are marked by both H3K9me3
methylation and bound by KAP1 and SETDB1 at the 39 end of the
gene. A small number of genes are also bound at the 39 end of the
transcript by ZNF274. We also observed a pattern in the level of
H3K9me3 methylation, with two maximum levels at about
position 62,850,000 and 63,400,000 and trailing off at position
63,250,00. This bimodal pattern also occurs in the KAP1 and
SETDB1 binding data and is even more apparent when viewing a
wider view of the region. This position, marked in the figure by
vertical black line, also corresponds with the position of rs159870
(chr19: 63239261) and there is break in synteny with rodent
genomes in this zone.
Comparison of IBD sharing among different populations
We next examined patterns of IBD sharing at the SNP with the
highest LOD score on chromosome 19 (rs159872). We compared
the proportion of IBD case pairs in different populations to
determine whether there are particular populations that contribute
to more IBD case pairs at this locus; and found the Tasmanian
population has the highest proportion of IBD case pairs. When
compared with all other combined Australian populations, the
Tasmanian population significantly contributed more IBD case
pairs at this locus (p = 0.004); and was significant when compared
with all other combined non-Tasmanian populations
(p = 5.4461025; Table 2).
Networks of cases and controls sharing haplotypes on
chromosome 19
Figure 4 shows networks of cases and controls sharing
haplotypes IBD at the SNP with the highest LOD score on
chromosome 19. The biggest cluster comprises 10 cases sharing a
haplotype in which 4 cases were from Melbourne, 4 from New
Zealand, 1 from Sydney and 1 from USA. Another big cluster
includes 2 cases from Melbourne, 3 cases from Tasmania and 4
cases from New Zealand (Fig. 4A). More generally, there are
more networks of cases sharing haplotypes than controls.
Discussion
We have applied BEAGLE fastIBD for the detection of rare MS
variants utilising a large-scale GWAS dataset. We identified a high
linkage signal on chromosome 19 with a p-value of 1.961026
(LOD=4.65). In classical linkage analysis in small families,
individuals are closely related and the segments of IBD tend to
be fairly long (.10 cM) which are easier to detect and less
independent than IBD mapping, the generally-accepted threshold
for genome-wide significance is p = 2.061025 [41]; while GWAS
has more independent tests than IBD mapping, the threshold of
genome-wide significance is around p= 5.061028 [42], so the
threshold of p-value for IBD mapping genome-wide significant
should be between 5.061028 and 2.061025. Recently, researchers
demonstrated that the genome-wide significance thresholds for
IBD mapping depend on the IBD segment size detected or IBD
generations [31]. For example, an IBD segment size of 2 cM
corresponds to 25 generations and the genome-wide significance
threshold is 2.061026, while the segment size of 3.2 cM
corresponds to 15 generations and the genome-wide significance
threshold is 4.061026 [31]. The strongest non-HLA linkage signal
we detected in this study used a 3 cM segment size; which
corresponds to 17 generations, thus the genome-wide significance
threshold is between 4.061026 and 2.061026. As such, the
linkage signal on chromosome 19, with a p-value of 1.961026, was
determined to be genome-wide significant.
Causal relationship between genes in linkage region and
MS
Most genes in this linkage region are zinc finger (ZNF) proteins
of which 32 genes have been suggested to be transcriptional
regulators [43] (http://genome.ucsc.edu/). Seven genes (ZNF134,
ZNF135, ZNF154, ZNF549, ZNF606, ZNF671 and ZSCAN1) in this
region belong to the Kru¨ppel family of ZNF genes. Only a few
ZNF genes in this region have known vertebrate homologues and
it includes a number of primate specific KRAB-ZNF genes [44].
In humans KRAB-ZNF genes number about 400 and make up the
largest group of C2H2 transcription factors [45] which are
typically expressed at low levels and involved in cell specific
silencing and driving different cell lineages.
Detailed analysis of genes in this region did not reveal any direct
links with MS. However examination of their expression profiles in
published data revealed a shared early developmental CNS
specific expression profile with 22 genes in this region being
members of the expression module M20 described in [36],
characterised by higher expression in all brain regions in early
foetal time points followed by decreased expression prior to birth
and very low expression thereafter. The M20 network of genes has
a strong correlation with both neuronal differentiation and
neuronal migration and a strong negative correlation with
myelination [36].
Epigenetic mechanisms such as histone modification and DNA
methylation are responsible for silencing many specific transcrip-
tion factors including zinc finger genes, and the 39 end of many
ZNF genes are specifically covered by H3K9me3 [46]. The zinc
finger gene ZNF274, located within the linkage region, is involved
in gene silencing through recruitment of the histone methytrans-
ferase complex TRIM28 (KAP1)/SETDB1 to the 39 end of
specific ZNF genes [40]. Examination of H3K9me3, KAP1 and
SETDB1 binding data, confirms that many of the genes in the
linkage region are covered by H3K9me3 at their 39end (Fig. 3).
ZNF274 also interacts with p75NTR and is predicted to play a role
in programmed cell death during development [47]. A number of
the genes in this area are also highly expressed in differentiated
Table 2. Comparison of IBD case pairs among different
populations (rs159872 with the highest LOD score on chr19;
LOD= 4.65).
Population No. case
No. IBD
case pairs
% IBD
case pairs p-value
TAS 308 7 14.8061025 Ref.
Mel 841 32 9.0661025 0.22
Newc 111 0 0.00 1.00
Syd 541 14 9.5861025 0.32
Other 32 0 0.00 1.00
AUS (non-TAS) 1525 46 3.9661025 0.004
NZ 540 14 9.6261025 0.32
US 879 22 5.7061025 0.033
Non-TAS 2944 82 1.8961025 5.4461025
*% IBD case pairs = IBD pairs/case6(case-1)/2; (Fisher’s Exact Test).
doi:10.1371/journal.pone.0056379.t002
IBD Mapping for Rare Variants in MS
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human neural cells compared to earlier stems cells (ZNF549,
ZNF324, ZNF548, ZNF264, ZNF671, ZSCAN1 and ZSCAN18 are
members of cluster A [48]). There is very little available evidence
for involvement in immune cell activity for genes in this region.
ZNF304 is implicated in lymphocyte activation [49] and ZNF274
has very high expression in activated eosinophils compared with
other immune cell types [50]. Other genes in this region have
relatively low expression and are not differentially regulated
between immune cell types [50], as viewed in the immunological
genome [51].
Together these findings suggest that many of the genes in this
cluster may be involved in early differentiation of neuronal cells
and potentially the silencing of genes required for myelination.
Expression of ZNF genes is commonly detected in foetal brain and
they are predicted to be involved in development of the nervous
system, a KRAB zinc finger cluster on chromosome 8 has also
been proposed to be involved in regulation of CNS development
[52]. Although other clustered genes families have been shown to
be co-expressed in cell types or tissues, previous studies have failed
to identify coordinated expression of KRAB-ZNF gene clusters
[44]. However earlier experiments did not examined the very early
timepoints in CNS tissues included in the Kang dataset [36].
These expression profiles described in the M20 module are
supported by two independent data set of both exon array level
and RNA-seq expression data in early human CNS development
available at the Allan Brain Atlas (http://developinghumanbrain.
org/).
Thus this may be an example of a gene cluster of KRAB -ZNF
genes exhibiting coordinated expression regulation, indicating the
presence of a genomic regulatory block (GRB). Such regions are
usually transcription factors controlled by highly conserved
noncoding regions. Although the identification of GRBs remains
difficult the evidence that we have collated is suggestive of two
genomic regulatory blocks within the linkage region, interrupted at
the position of SNP rs159870 where there is an absence of
H3K9me3 methylation and a break in synteny (reviewed in [53]).
The underlying cause for susceptibility in this region could
therefore be due, not to differences in a specific gene expression or
protein product, but to differences in the tight expression
regulation of a GRB. As mentioned above, many of the C2H2
zinc finger genes in this region have an expression profile
consistent with silencing of genes required for myelination.
Further analysis needs to be undertaken to examine if these genes
are co-regulated in demyelination and remyelination as well as
CNS developmental states. Unfortunately, due to the species
specificity of many of the KRAB-ZNF genes and the absence of
rodent homologues of genes in this region, data from non-human
models of demyelination and remyelination may not be useful.
Ideally, re-sequencing is the next step to refine this potential
signal further. Unfortunately, resequencing of the region would be
complicated since there are many gene duplications in this linkage
region.
For the SNP (rs159872) with the highest LOD score on
chromosome 19, we hypothesise that there are some difference
between cases and controls sharing haplotypes in the linkage
region among different populations. We found the Tasmanian MS
population has the highest proportion of case IBD sharing,
significantly higher than non-Tasmanian combined populations as
well as other non-Tasmanian combined Australian populations.
While Tasmania has the highest prevalence of MS in Australia, it
is generally agreed that this is primarily driven by environmental
effects related to, sunlight and/or vitamin D [54]. However there
is also a modest founder effect in Tasmania [55], which might
result in an increase in MS susceptibility driven by rare variants
IBD. Interestingly, we found there are more big networks of cases
sharing haplotypes than controls, and one big case network
comprises 3 Tasmanian cases, 4 New Zealand cases and 2 cases
from Melbourne, which may indicate the potential causal variants
or gene mutations exist in those big case networks. However, this
Figure 4. Networks of cases and controls sharing haplotypes IBD at the SNP with the highest LOD score on chromosome 19. (A)
Networks of cases sharing haplotypes in common at the linkage region on chromosome 19. (B) Networks of controls sharing haplotypes in common
at the linkage region on chromosome 19. Each dot represents an individual and each line connects pairs of individuals who share a haplotype. There
are more big networks of cases sharing haplotypes than controls.
doi:10.1371/journal.pone.0056379.g004
IBD Mapping for Rare Variants in MS
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SNP falls in a region of low/none methylation and correlates with
a break in syteny, the significance of which is unclear.
Technical considerations
Even though Beagle fastIBD is several orders of magnitude
faster than Beagle IBD, IBD analysis remains moderately
computationally intensive on a dataset of this size (8,977
individuals and 274,735 SNPs). For instance, on chromosome 2
with 22,607 SNPs, the computation time for each run was
approximately 4.6 hours with memory requirement of 3.3 GB on
2 cores of a SGI Altix ICE 8200 HPC cluster computer node.
However, we also found IBD analysis limitations: it is only
suited to discover rare variants if all variants act in the same
direction in one gene. For example, the identified rare variants in
BRCA1 and BRCA2 gene all increase risk of breast cancer [56], and
the four rare variants identified in IFIH1 gene all protect against
type I diabetes [18]. If some rare variants increase risk while others
in the same gene decrease risk then the signal in the region will be
attenuated. In addition, we found IBD analysis is very sensitive to
genotyping error, resulting in reducing signal strength. The linkage
signal detected depends on a lot of markers or long haplotypes,
containing up to hundreds of SNPs, a single error occurring in
reading a single marker significantly reduces the signal. In our
data, samples came from different GWAS using different
genotyping chips in different locations, which at least in part,
may decrease the potential signal strength from our study.
Furthermore, resequencing would be complicated by gene
duplication and repeat regions, since the linkage region detected
in this study had many gene duplicates, thus replication in other
independent dataset is needed.
The optimal method to detect rare disease-causing variants is
whole genome sequencing of thousands of samples. When this
becomes affordable, there will remain a role for IBD analysis to
prioritize regions for follow-up analysis and minimize the massive
multiple testing burden. Just as linkage analysis is now used to
identify regions for follow-up in whole genome sequencing and
exome sequencing of Mendelian disease families, and linkage
analysis can be used to weight regions for GWA analysis [26].
In summary, we have applied IBD analysis to a large complex
disease GWA dataset and identified a linkage signal with genome-
wide significance, although it. While our most significant result is
of equivocal significance, and lies in a region that is hard to
validate via sequencing, we believe IBD analysis has considerable
potential, particularly to help interpret whole-genome sequencing
data in complex trait studies.
Supporting Information
Figure S1 Principal components analysis for the data-
set.Most individuals in the dataset are of predominantly northern
European ancestry (right hand side), but some have southern
European ancestry (left hand side) (one dot for each individual).
(TIF)
Figure S2 Fitting Poisson model for the IBD data. All the
four real lines in these four modules fit well with the default lines,
suggesting Poisson model is appropriate for this data. The
residuals of the green region are higher than others.
(TIF)
Figure S3 Fitting negative binomial model for the IBD
data. All the four real lines in these four modules fit not well with
the default lines, suggesting negative binomial model is not suitable
for this IBD data.
(TIF)
Figure S4 Fitting linear model for the IBD data. All the
four real lines in these four modules fit not well with the default
lines, suggesting linear model is not suitable for this IBD data.
(TIF)
SR_commands S1 1) Fitting and testing model for IBD
data. 2) Plot of residuals from the Poisson model converted to
LOD scores. 3) Network analysis.
(PDF)
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